Trigeminal Neuralgia
Trigeminal Neuralgia
What Patients and Referring Providers Need to Know
Patients with trigeminal neuralgia often tell me the same story: a sudden, electric jolt of pain in the face, set off by something as ordinary as brushing their teeth, a breeze on the cheek, or the first bite of breakfast. Many have already seen a dentist, and some have had teeth pulled, before anyone put a name to it. It's called one of the most painful conditions in medicine for a reason. It is also one of the most treatable.
This page covers what trigeminal neuralgia is, how it's diagnosed, why medication is almost always the right place to start, and what the surgical options look like when medication stops working or can't be tolerated.
What Is Trigeminal Neuralgia?
The trigeminal nerve (the fifth cranial nerve) carries sensation from the face to the brain. It leaves the brainstem as a single root, then divides into three branches: V1 (forehead and eye), V2 (cheek, upper lip, upper teeth), and V3 (jaw, lower lip, lower teeth). Trigeminal neuralgia (TN) is a disorder of that nerve that produces brief, severe attacks of pain in one or more of those territories, almost always on one side of the face.
It is uncommon but not rare. Estimates run roughly 4 to 13 new cases per 100,000 people each year. It is more common in women and becomes more frequent with age, with most patients first affected after 50.
What It Feels Like
Classic trigeminal neuralgia has a very recognizable pattern:
- Sudden, electric, stabbing, or shock-like pain lasting from a fraction of a second up to about two minutes
- One side of the face, in the distribution of one or more trigeminal branches
- Triggered by light touch or ordinary activity: chewing, talking, brushing teeth, shaving, applying makeup, a cool breeze
- Pain-free periods between attacks, sometimes for weeks or months at a time, followed by clusters of frequent attacks
Some patients also have a dull, burning, or aching background pain between the shocks. This is sometimes called TN with concomitant continuous pain. It matters because it affects which treatments tend to work best.
What Causes It?
Trigeminal neuralgia is classified into three groups based on cause:
- Classical TN, the most common form. A blood vessel, usually the superior cerebellar artery, presses against the trigeminal nerve root where it leaves the brainstem. Over time, the constant pulsation wears down the nerve's insulating myelin, and the nerve starts to misfire. MRI shows a vessel compressing and distorting the nerve.
- Secondary TN, caused by an identifiable underlying disease. Multiple sclerosis is the most common. A small percentage of people with MS develop TN, often at a younger age and sometimes on both sides. Less often, a benign tumor such as a meningioma or vestibular schwannoma is pressing on the nerve.
- Idiopathic TN, where the symptoms are typical but imaging shows neither vascular compression nor another cause.
How It's Diagnosed
The diagnosis is made primarily from the history: the character of the pain, where it is, how long each attack lasts, and what sets it off. A normal neurological exam supports classical TN. New numbness in the face or weakness in the chewing muscles raises the possibility of a secondary cause.
Every patient should have an MRI of the brain with high-resolution, thin-cut sequences through the brainstem (such as CISS or FIESTA), with and without contrast. This does two jobs: it rules out MS, tumors, and other structural causes, and it shows whether a blood vessel is compressing the nerve. That second finding is central to deciding whether a patient is a good candidate for microvascular decompression later on.
Medication Comes First
In my practice, and in every major guideline, the first line of treatment for trigeminal neuralgia is medication, not surgery. Most patients respond well, many for years.
Carbamazepine or Oxcarbazepine
For patients: These are anti-seizure medications that calm the overactive nerve. Most people with classical TN get substantial relief, often within a few days of reaching an effective dose. The dose is started low and increased gradually. Common side effects are drowsiness, dizziness, and unsteadiness, especially in older adults. Your blood counts, sodium level, and liver function are checked periodically.
For providers: Carbamazepine (typically started at 100–200 mg twice daily and titrated to 200–1,200 mg/day) and oxcarbazepine (typically 300–1,800 mg/day) are first-line per the AAN/EFNS and EAN guidelines. Oxcarbazepine is often better tolerated but carries a higher rate of hyponatremia. Screen for HLA-B*15:02 before carbamazepine in patients of Asian ancestry given the risk of SJS/TEN. Monitor CBC, sodium, and LFTs, and watch for interactions from CYP3A4 induction, including with oral anticoagulants and oral contraceptives.
When First-Line Drugs Fall Short
For patients: If the first medication doesn't fully control the pain or causes side effects you can't live with, other medicines can be added or substituted. Many patients do well on a combination at lower doses of each.
For providers: Lamotrigine, gabapentin, pregabalin, and baclofen have supporting evidence as add-on or alternative therapy, though it is weaker than for sodium channel blockers. Severe acute exacerbations may call for short-term hospital management, including IV fosphenytoin or lidocaine. Opioids are not effective long-term for TN and are not recommended.
Surgery comes into the conversation when medications stop working or when the doses needed to control the pain cause side effects that interfere with daily life. Because medications often lose effectiveness over the years, a large share of patients reach that point eventually.
Surgical and Procedural Options
There are three broad categories. Which one is right depends on age, overall health, MRI findings, the type of pain, and how the patient weighs durability of relief against procedural risk.
Microvascular Decompression (MVD)
For patients: MVD is the only treatment that addresses the underlying cause of classical TN. Through a small opening behind the ear, I move the blood vessel away from the nerve and place a tiny Teflon or cotton cushion between them. Nothing is cut or damaged, so facial sensation is preserved. Most patients wake up with the pain gone, and it offers the longest-lasting relief of any option.
For providers: MVD is the preferred first surgical option for medically refractory classical TN with neurovascular compression on MRI in patients fit for general anesthesia (EAN 2019). In Barker's series of 1,185 patients (NEJM 1996), 82% had complete relief immediately after surgery, and about 70% remained free of pain without medication at 10 years. Major risks are low but real, including ipsilateral hearing loss (~1–2%), CSF leak, and facial numbness, with perioperative mortality around 0.2% in high-volume series.
Stereotactic Radiosurgery (Gamma Knife)
For patients: Radiosurgery delivers a precisely focused dose of radiation to the trigeminal nerve root, with no incision and usually as a same-day outpatient treatment. Relief is not immediate. It typically begins weeks to a few months after treatment. It is a good option for patients who are older, have significant medical conditions, or prefer to avoid open surgery.
For providers: Initial pain response is reported in roughly 75–90% of patients, with a median latency of about 1–3 months. Durability is lower than MVD: roughly half remain pain-free without medication at 3–5 years. New facial numbness occurs in about 10–20%, rising with dose and with repeat treatment. Radiosurgery is a reasonable choice for MS-related TN and for patients who are poor candidates for general anesthesia.
Needle-Based Rhizotomy
For patients: In these short procedures, a needle is passed through the cheek to the trigeminal ganglion under imaging guidance, and the nerve is deliberately injured just enough to interrupt the pain signals. The three techniques are balloon compression, radiofrequency (heat) lesioning, and glycerol injection. Relief is usually immediate. The trade-off is some permanent facial numbness, and pain tends to return sooner than after MVD, though the procedure can be repeated.
For providers: Percutaneous procedures are well suited to elderly or medically frail patients, patients with MS, and recurrence after prior surgery. Immediate relief rates are high (>85%), but median time to recurrence is shorter than with MVD. Sensory loss is expected, and a small subset develops dysesthesia or, rarely, anesthesia dolorosa. Masseter weakness is transient and common after balloon compression. Radiofrequency lesioning should avoid V1 when possible given the risk of corneal numbness.
| Option | Relief begins | Durability | Facial numbness | Best suited for |
|---|---|---|---|---|
| MVD | Immediately | Longest; ~70% pain-free at 10 years | Uncommon | Healthy patients with vascular compression on MRI |
| Gamma Knife | Weeks to months | Moderate; ~50% pain-free at 3–5 years | ~10–20% | Older or higher-risk patients; MS; preference to avoid incision |
| Percutaneous rhizotomy | Immediately | Shorter; repeatable | Expected | Frail patients, MS, recurrence after prior treatment |
What Microvascular Decompression Involves
MVD is performed under general anesthesia and typically takes two to three hours.
- Positioning and monitoring. The patient is positioned on their side. Hearing and facial nerve function are monitored throughout the operation to protect those nearby nerves.
- Small opening behind the ear. A short incision behind the ear and a small opening in the skull, roughly the size of a quarter, give access to the space where the trigeminal nerve leaves the brainstem.
- Finding the compression. Under the operating microscope, the nerve root is inspected along its full length to find the vessel or vessels pressing on it.
- Decompression. The vessel is gently moved away from the nerve, and a small shredded Teflon pad is placed between them to keep them apart.
- Closure. The covering of the brain is closed watertight, the bone opening is reconstructed, and the incision is closed.
Recovery After MVD
| Timeframe | What’s typical |
|---|---|
| Day of surgery | Overnight monitoring; most patients notice the shock-like pain is gone on waking |
| Hospital stay | Typically 1–3 nights |
| Weeks 1–2 | Incisional soreness, fatigue, and some headache are common; walking encouraged; no heavy lifting or straining |
| ~2 weeks | Wound check and follow-up visit |
| Weeks to months | TN medications tapered off under supervision |
| 4–6 weeks | Most patients back to work and normal activity |
A minority of patients have a short period of lingering or intermittent pain while the nerve settles down, which usually fades over several weeks. Medications are tapered gradually rather than stopped abruptly.
Risks and Complications
Every option carries some risk, and the right choice is the one whose trade-offs fit the patient. For MVD specifically:
- Hearing loss on the operated side, in roughly 1–2% of patients. Intraoperative monitoring is used to reduce this risk.
- CSF leak from the incision or through the nose, uncommon and usually managed without further surgery
- Facial numbness or weakness, usually mild and temporary
- Double vision from irritation of nearby nerves, rare and typically temporary
- Stroke, bleeding, or infection, rare but serious, as with any intracranial operation
- Recurrence of pain over time in a minority of patients, which can be treated with medication, repeat surgery, radiosurgery, or a percutaneous procedure
A Note to Referring Providers
I'm happy to see patients with trigeminal neuralgia at any stage, including those who are still controlled on medication and want to understand their options. The most useful referral includes a brain MRI with and without contrast plus thin-cut high-resolution sequences through the posterior fossa (CISS, FIESTA, or equivalent; “trigeminal protocol”), a list of medications tried with doses and reasons for stopping, and any recent sodium, CBC, and liver labs. Patients who fail or cannot tolerate an adequate trial of carbamazepine or oxcarbazepine are appropriate for surgical consultation.
The following features suggest secondary TN or an alternative diagnosis and warrant expedited imaging and referral: objective sensory loss in the face, bilateral symptoms, onset under age 40, other cranial nerve deficits (hearing loss, diplopia, facial weakness), or hearing loss or imbalance suggesting a cerebellopontine angle lesion. A patient unable to eat or drink because of pain, or with severe medication toxicity, warrants a same-day call to the office rather than routine scheduling.
A Note to Patients
If you've been living with this kind of pain, it's worth hearing clearly: trigeminal neuralgia is real, it is recognizable, and it is very treatable. Most patients get good control with medication alone. For those who don't, or who can't live with the side effects, there are effective procedures, including one that targets the cause and preserves normal feeling in the face. My goal in a first visit is to confirm the diagnosis, make sure the medication plan has been fully optimized, and give you a clear picture of your options if and when you need them.
Questions About Facial Pain?
Northside Advanced Neurosurgery Associates
2200 Medical Center Blvd, Ste 350, Lawrenceville, GA 30046
Call 678-312-2700 | Monday–Friday, 8:00 AM–4:00 PM
Selected Sources
- Bendtsen L, et al. European Academy of Neurology guideline on trigeminal neuralgia. European Journal of Neurology, 2019;26(6):831–849.
- Cruccu G, et al. AAN-EFNS guidelines on trigeminal neuralgia management. European Journal of Neurology, 2008;15(10):1013–1028.
- Barker FG, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. New England Journal of Medicine, 1996;334:1077–1083.
- Kondziolka D, et al. Long-term outcomes of Gamma Knife radiosurgery for classic trigeminal neuralgia. Journal of Neurosurgery, 2010.
- Headache Classification Committee of the International Headache Society. International Classification of Headache Disorders, 3rd edition (ICHD-3), 13.1.1 Trigeminal neuralgia. Cephalalgia, 2018.
- Cleveland Clinic Journal of Medicine. Guidelines for the management of trigeminal neuralgia. 2023;90(6):355.
- StatPearls (NCBI Bookshelf). Trigeminal Neuralgia.
This page is provided for general educational purposes and does not replace an individualized evaluation. If you are experiencing a medical emergency, call 911 or go to the nearest emergency room.